Ionis Pharmaceuticals, Inc. filed a Form 8-K with the SEC on September 23, 2026, disclosing positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy.
Key Highlights
- Primary endpoint met: Sefaxersen achieved statistically significant and clinically meaningful improvements in proteinuria reduction compared to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR).
- Dosing and administration: Sefaxersen is a once-monthly subcutaneous injection designed to enable self-administration for people with IgAN.
- Safety profile: The safety and tolerability profile was consistent with previously reported data, with no new safety signals identified, according to the filing.
- Study continuation: The IMAgINATION study will continue as a blinded study to evaluate change in kidney function over two years, as measured by estimated glomerular filtration rate at week 105.
- Disease burden: IgA nephropathy leads to end-stage kidney disease in up to 50% of patients within 20 years after diagnosis and affects at least 25 adults per million worldwide each year, according to the filing.
- Commercial terms: Roche licensed sefaxersen from Ionis; Ionis received an upfront payment, license fee, and development milestone payments, and is eligible to receive regulatory and sales milestone payments as well as tiered royalties on net sales.
IMAgINATION Phase 3 Interim Results: What Ionis and Roche Disclosed
According to the filing, Ionis Pharmaceuticals (NASDAQ:ION) and its partner Roche Holding Ltd. reported positive prespecified interim results from the Phase 3 IMAgINATION study evaluating sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint, with sefaxersen demonstrating statistically significant and clinically meaningful reductions in proteinuria compared to placebo at 37 weeks. The filing notes that proteinuria is "a key indicator of kidney damage" and that a reduction in UPCR "is strongly associated with the preservation of long-term kidney function."
The filing describes IgAN, also known as Berger's disease, as "a chronic and progressive autoimmune kidney disease" typically diagnosed before the age of 40 years. The study will continue in blinded fashion to assess estimated glomerular filtration rate at week 105 as a measure of kidney function over two years. The company disclosed that interim analysis data will be presented at an upcoming medical congress and shared with health authorities, with the stated goal of bringing the treatment to patients as soon as possible.
The filing notes that Roche licensed sefaxersen from Ionis for the treatment of complement-mediated diseases. The disclosed agreement provides Ionis with an upfront payment, license fee, development milestone payments, and eligibility for regulatory and sales milestone payments as well as tiered royalties on net sales of sefaxersen. The filing includes forward-looking statements regarding the therapeutic and commercial potential of sefaxersen, which the company cautioned are subject to risks and uncertainties and should not be relied upon.
What Was Disclosed
Ionis Pharmaceuticals filed an 8-K on September 23, 2026, reporting that the Phase 3 IMAgINATION study of sefaxersen in IgAN met its primary endpoint at 37 weeks, with no new safety signals, and that the study will continue to week 105.



Please wait processing your request...